Replies to post #192378 on Biotech Values

[DewDiligence]

AMGN GS webcast: The EVP of R&D implicitly disparaged SNY/REGN for allowing PCSK9 dose titration. It came across as silly book talking, IMO.

Other than that, the webcast offered no insights on Repatha or the PCSK9 market, as far as I could tell.